Chris Baker

Method of Assessing Skin Cancerization and Keratoses(TM) (MASCK (TM)): development and photographic validation in multiple anatomical sites of a novel assessment tool intended for clinical evaluation of patients with extensive skin field cancerization

Christopher Baker, Amelia James, Madeleine Supranowicz, Lynda Spelman, Stephen Shumack, Judith Cole, Warren Weightman, Robert Sinclair, Peter Foley

Journal article  |  2022  |  CLINICAL AND EXPERIMENTAL DERMATOLOGY

BACKGROUND: A range of 'field-directed' treatments is available for the management of extensive skin field cancerization (ESFC), b..

Pityriasis rubra pilaris treatment options: A retrospective case series from a tertiary hospital

Sarah Ringin, Chris Baker, Peter Foley, Benjamin Daniel

Journal article  |  2021  |  DERMATOLOGIC THERAPY

Pityriasis rubra pilaris (PRP) is a group of uncommon chronic inflammatory skin conditions with unclear pathophysiology and etiolo..

SARS-CoV-2 (COVID-19) vaccination in dermatology patients on immunomodulatory and biologic agents: Recommendations from the Australasian Medical Dermatology Group

Charlie Wang, Marius Rademaker, Bruce Tate, Christopher Baker, Peter Foley

Journal article  |  2021  |  AUSTRALASIAN JOURNAL OF DERMATOLOGY

As the phase III COVID-19 vaccine trials excluded patients on immunosuppressive treatments, or patients with significant autoimmun..

Management of chronic hand and foot eczema. An Australia/New Zealand Clinical narrative

Marius Rademaker, Katherine Armour, Christopher Baker, Peter Foley, Kurt Gebauer, Monisha Gupta, Gillian Marshman, Alicia O'Connor, Diana Rubel, John Sullivan, Li-Chuen Wong

Journal article  |  2021  |  AUSTRALASIAN JOURNAL OF DERMATOLOGY

Chronic hand/foot eczemas are common, but treatment is often challenging, with widespread dissatisfaction over current available o..

Treatment modalities and risk of adverse events associated with biologic therapy: A 10-year observational review of the Australasian Psoriasis Registry

Brent J Doolan, Digsu Koye, Joanna Ling, Geoffrey D Cains, Christopher Baker, Peter Foley, Con Dolianitis

Journal article  |  2021  |  AUSTRALASIAN JOURNAL OF DERMATOLOGY

BACKGROUND: Psoriasis is a chronic inflammatory disease affecting ~2-3% of the Australasian population. Therapeutic options includ..

COVID-19 and the use of immunomodulatory and biologic agents for severe cutaneous disease: An Australian/New Zealand consensus statement

Charlie Wang, Marius Rademaker, Christopher Baker, Peter Foley

Journal article  |  2020  |  AUSTRALASIAN JOURNAL OF DERMATOLOGY

Patients on immunomodulators, including biologic agents and new small molecular inhibitors, for cutaneous disease, represent a pot..

Real world experience using Ciclosporin in psoriasis: Efficacy and toxicity in the Australasian Psoriasis Registry

William Berry, Benjamin S Daniel, Christopher Baker, Peter Foley

Journal article  |  2020  |  AUSTRALASIAN JOURNAL OF DERMATOLOGY

Infliximab drug survival in chronic plaque psoriasis: follow-up of the product familiarisation program

William Berry, Benjamin Daniel, Rebecca Nguyen, Chris Baker, Peter Foley

Journal article  |  2020  |  AUSTRALASIAN JOURNAL OF DERMATOLOGY

Advice regarding COVID-19 and use of immunomodulators, in patients with severe dermatological diseases

Marius Rademaker, Christopher Baker, Peter Foley, John Sullivan, Charlie Wang

Journal article  |  2020  |  AUSTRALASIAN JOURNAL OF DERMATOLOGY

Dermatologist attitudes toward ciclosporin use in atopic dermatitis

Kevin Phan, Olivia Charlton, Chris Baker, Peter Foley, Saxon D Smith

Journal article  |  2020  |  JOURNAL OF DERMATOLOGICAL TREATMENT

Ciclosporin (CsA) is a systemic immunosuppressive agent indicated for use in the treatment of patients with recalcitrant atopic de..